Richard Aarnio

Richard Aarnio serves as a Senior Researcher at the Turku PET Centre and Doctoral Researcher in Imaging and Clinical Diagnostics at the University of Turku, Finland. His work advances PET imaging methodologies for neurological and metabolic disorders, with expertise in radiotracer development and clinical translation.

His research concentrates on neuroinflammation imaging in Multiple Sclerosis and Parkinson's Disease using novel tracers like [11C]SMW139, synaptic density mapping in neurodegeneration, and metabolic imaging in Type 2 Diabetes. Key projects include multicenter studies on microglial activation and SGLT2 inhibitor effects on brain metabolism, reflecting his dual focus on technical innovation and clinical applications.

Analysis of his 2024-2025 publications reveals a strong trend toward methodological rigor in radiometabolite analysis and translational impact across neurology and endocrinology. His work frequently bridges animal models to human studies, with growing emphasis on standardized protocols for emerging targets like the P2X7 receptor.

Aarnio maintains active research engagement through multicenter clinical trials and international collaborations, particularly with Australian and Swedish institutions. While completing his doctoral degree, he contributes significantly to the Turku PET Centre's mission through technical leadership in image analysis and tracer validation.

As part of the Turku PET Centre's multidisciplinary team, he accesses state-of-the-art cyclotron facilities, multimodal imaging platforms, and clinical cohorts. His role emphasizes collaborative science within Finland's national imaging infrastructure, focusing on developing biomarkers for neuroinflammatory and metabolic disorders.